# DSIP & Epithalon: What the Research Says About Sleep and Circadian Peptides

Evidence & Research Status

Evidence LevelPreclinical / Early-Stage Research

FDA StatusNot FDA-approved for human use

Regulatory StatusResearch Use Only (RUO) — not for human consumption

Last UpdatedAugust 5, 2026

What This Article Covers

DSIP (delta sleep-inducing peptide) and Epithalon (also written Epitalon or Epithalone) are frequently discussed together because both show up in circadian and longevity-adjacent research, but their…

Primary References [sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/0149763484900228) [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/6145137/) [journals.lww.com](https://journals.lww.com/ejanaesthesiology/fulltext/2001/07000/delta_sleep_inducing_peptide.1.aspx)

Evidence Level reflects the general state of published research for this compound category and is not a claim about the safety, efficacy, or approval status of any product sold on this site. All compounds are offered strictly for research use.

*By Charles Fowler, Founder of Portal to Wellness · Last reviewed: July 2026 · ~9 min read*

*A quick note on why I wrote this: I’m not a doctor or a sleep researcher — I’m a founder who spends my days reading the peptide literature and vetting what we carry. DSIP and Epithalon are both filed under “sleep peptides,” but they come from different tissue systems and act on sleep through genuinely different mechanisms. Below is a plain-language walk-through of what’s actually been published on each. Everything here is educational only, reflects published, publicly available research, and is not medical advice.*

Key Takeaways

- DSIP and Epithalon are both studied as “sleep peptides” but act through different mechanisms and tissue origins.
- DSIP research centers on hypothalamic effects on slow-wave (delta) sleep and diurnal rhythm.
- Epithalon’s literature focuses on pineal-derived effects on telomerase activity and melatonin synthesis.
- Neither peptide is FDA-approved; both are sold strictly for laboratory research use only.

## Two different systems, one shared research theme

DSIP (delta sleep-inducing peptide) and Epithalon (also written Epitalon or Epithalone) are frequently discussed together because both show up in circadian and longevity-adjacent research, but their tissue origins and proposed mechanisms are quite different. DSIP is a nonapeptide first identified in the hypothalamus in the early 1970s, studied for its direct effects on sleep architecture. Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a component isolated from the pineal gland, studied primarily for effects on the pineal gland’s hormonal output and on telomerase activity — sleep and circadian effects are downstream of a broader proposed geroprotective mechanism.

## DSIP: research on slow-wave sleep and stress regulation

DSIP was discovered in 1977 by Schoenenberger and Monnier, isolated from the cerebral venous blood of rabbits during studies on sleep-regulating substances. Despite the name, its research profile extends well beyond sleep alone:

- **Delta (slow-wave) sleep architecture.** The peptide’s namesake effect: research indicates DSIP is involved in modulating delta wave sleep, the deep, restorative phase of the sleep cycle most associated with physical recovery, memory consolidation, and hormone release.
- **Neurotransmitter modulation.** DSIP has been shown to interact with GABAergic and serotonergic pathways in the research literature, both systems closely tied to sleep onset and maintenance.
- **Diurnal (daily) rhythm.** Human studies have found that plasma and brain DSIP concentrations show a marked diurnal variation — lower in the morning, higher in the afternoon — and that this pattern correlates with broader circadian rhythm markers, which is part of why DSIP is studied as a circadian-relevant peptide and not just a sleep-onset compound.
- **Broader research scope.** Beyond sleep, published research has also examined DSIP’s relationship to electrophysiological brain activity, neurotransmitter levels, locomotor and circadian patterning, hormonal levels, psychological performance measures, and interactions with the activity and withdrawal effects of other neuropharmacological compounds.

## Epithalon: pineal peptide research and telomerase activity

Epithalon was identified as the proposed active component of epithalamin, a bovine pineal gland extract studied for decades, primarily by Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology. The bulk of the published literature on Epithalon comes from this research tradition, though independent interest has grown in recent years:

- **Telomerase activation.** The most-cited mechanism in Epithalon research is its proposed ability to upregulate telomerase activity, with in vitro studies reporting increased telomere length in human cell lines following Epithalon exposure — either through direct telomerase upregulation or through alternative lengthening mechanisms, depending on the cell line studied.
- **Melatonin and pineal function.** Research also points to a direct influence on melatonin synthesis, consistent with Epithalon’s origin as a pineal-derived peptide, which is the basis for its inclusion in circadian-rhythm-focused research.
- **Broader geroprotective effects.** The literature describes additional proposed effects including antioxidant activity, neuroprotection, antimutagenic effects, modulation of interleukin-2 mRNA levels, effects on thymocyte mitogenic activity, and enhanced activity of several enzymes including acetylcholinesterase and telomerase itself. Researchers frame these collectively as “geroprotective” — slowing markers of biological aging — rather than as a single targeted mechanism.

As with other Khavinson-tradition peptides, it’s worth noting that most of this research originates from a concentrated group of research institutions, with independent replication still an active and ongoing area of interest outside that tradition.

## DSIP vs. Epithalon: different tools for different research questions

The clearest way to think about the distinction: DSIP’s research centers on direct, relatively fast-acting effects on sleep architecture and nervous system regulation — the kind of peptide studied for its acute effect on a night’s sleep quality. Epithalon’s research centers on slower, systemic effects on pineal hormonal output and cellular aging markers, with circadian rhythm support as one output of a broader mechanism rather than the primary target. Some longevity-focused research studies the two together on the theory that they address complementary layers — acute sleep architecture (DSIP) and longer-term circadian/cellular regulation (Epithalon) — though no clinical trials have tested that specific combination directly.

## Frequently Asked Questions

**Is DSIP the same thing as melatonin?**
No. Melatonin primarily regulates circadian timing (when you feel sleepy). DSIP’s research focus is on the architecture of sleep itself — particularly slow-wave delta sleep — through GABAergic and serotonergic pathways, a mechanistically distinct target from melatonin receptor activity.

**What’s the evidence that Epithalon affects aging, not just sleep?**
Epithalon’s most-cited research is on telomerase activity and telomere length in human cell lines, alongside proposed antioxidant and neuroprotective effects. Its sleep and circadian relevance stems from its pineal-gland origin and effects on melatonin synthesis, which researchers view as one piece of a broader geroprotective mechanism rather than the primary studied endpoint.

**Are DSIP and Epithalon FDA-approved?**
No. Neither peptide is FDA-approved for any use. Both are sold strictly for laboratory research use only, and neither has completed large-scale human clinical trials under Western regulatory frameworks.

**Do researchers study DSIP and Epithalon together?**
Some longevity-focused studies pair the two based on their complementary mechanisms — acute sleep-architecture effects from DSIP and longer-term circadian/cellular effects from Epithalon — though there is no published clinical trial data on that specific combination.

## References

- Delta-sleep-inducing peptide (DSIP): A review. [sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/0149763484900228)
- Delta-sleep-inducing peptide (DSIP): a review (PubMed). [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/6145137/)
- Delta sleep-inducing peptide, European Journal of Anaesthesiology. [journals.lww.com](https://journals.lww.com/ejanaesthesiology/fulltext/2001/07000/delta_sleep_inducing_peptide.1.aspx)
- Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. [pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/)
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. [pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/)

📚 Part of our [Sleep & Regeneration](https://portaltowellness.net/circadian-regulation-kit/) research guide.

*This article is for informational and educational purposes only. It is not medical advice and does not describe the diagnosis, treatment, cure, or prevention of any disease. Portal to Wellness does not sell products intended for human consumption or clinical use; all compounds referenced are sold strictly for laboratory research use only (RUO). Always consult a qualified healthcare professional before making any changes to your health routine.*

Update — July 25, 2026

On July 24, 2026, an FDA Pharmacy Compounding Advisory Committee voted 7-5 (one abstention) to recommend Epitalon for the 503A Bulks List, but voted against recommending emideltide/DSIP in a narrow ~7-6 vote (one abstention) — DSIP was the only one of seven peptides reviewed across the two-day meeting that the committee did not support. Both votes are non-binding: FDA has not approved either substance, must still issue a formal decision, and no vote (favorable or not) establishes clinical evidence of effectiveness or ineffectiveness. [Source: STAT News](https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/)

### Continue Your Research

Related Articles [Thymosin Alpha-1 & LL-37: What the Research Says About Immune-Modulating Peptides](https://portaltowellness.net/research/thymosin-alpha-1-ll-37-what-the-research-says-about-immune-modulating-peptides/) [Semax, Selank & Pinealon: What the Research Shows About Nootropic Peptides](https://portaltowellness.net/research/semax-selank-pinealon-what-the-research-shows-about-nootropic-peptides/)

Related Products [DSIP – 15mg/vial (Research Use Only)](https://portaltowellness.net/shop/dsip/) [Epithalon – 40mg/vial — Research Use Only](https://portaltowellness.net/shop/epithalon/) [GABA – 100mg/vial (Research Use Only)](https://portaltowellness.net/shop/gaba/)

Related Research Guide [Growth-Hormone Axis & Circadian Signalling Research](https://portaltowellness.net/circadian-regulation-kit/)

Related Category [Growth-Hormone Axis & Circadian Signalling Research](https://portaltowellness.net/circadian-regulation-kit/)

Related FAQ [General Research & Ordering FAQ](https://portaltowellness.net/faq/)

More Research [Browse the full PTW Research Hub →](https://portaltowellness.net/research/)

## Amounts used in the published research

### DSIP (Delta Sleep-Inducing Peptide)

**Every published human DSIP amount is the same one, given intravenously: 25 nmol/kg** — roughly 21 µg/kg. **No human subcutaneous or intramuscular study exists.** Just as important: the two properly blinded insomnia trials were essentially negative.

| Study | Amount | Route | n | Finding |
| --- | --- | --- | --- | --- |
| Schneider-Helmert 1981, healthy | 25 nmol/kg | Slow IV infusion, single | 6 | Sleep increased 59% over 130 min |
| Monti 1987, insomnia | 25 nmol/kg | IV, 4 nights, double-blind crossover | — | “Little clinical significance” |
| Bes 1992, insomnia | 25 nmol/kg | IV, double-blind parallel | 16 | Effects “weak,” not therapeutic |
| Dick 1983, withdrawal | 25 nmol/kg | IV | 67 | Open-label, uncontrolled; 27% unevaluable |

Animal: 120 nmol/kg SC (cat), 10 µg/kg IP and 60 µg/kg (rat). **Plasma half-life is extremely short** — 4.0 min in dog, 2.9 min in monkey, 2.0 min in rat. No human PK published. No approval in any country.

### Epithalon — and the substance it keeps getting confused with

**Epithalon and Epithalamin are two different substances.** Epithalamin is a crude *bovine pineal gland extract* . Epitalon / Epithalon is a *synthetic tetrapeptide* (Ala-Glu-Asp-Gly). Nearly every “5–10 mg injected” figure circulating online is Epithalamin extract dosing being misapplied to the synthetic peptide. In a primate comparison the two differed roughly **500-fold** in potency — 10 µg/animal/day of Epitalon versus 5 mg/animal/day of Epithalamin.

| Substance | Amount | Route | Detail |
| --- | --- | --- | --- |
| Epithalamin (extract) | 10 mg | Intramuscular | Korkushko 2006 — 5 injections at 3-day intervals, repeated every 6 months for 3 years; 70 elderly cardiac patients, 12-year follow-up, 28% lower all-cause mortality |
| Epitalon (synthetic) | 5.0 µg per eye | Parabulbar | Retinitis pigmentosa, 162 patients, 10 consecutive days |
| Epitalon (synthetic) | 0.5 mg/day | Sublingual | 75 women, 20 days, melatonin and clock-gene endpoints |
| Animal (rodent) | 0.1–2.5 µg/rat SC; 7–10 µg/kg IM; 1 µg/mouse SC | Various | Often 5 days per month, life-long |
| In vitro | 0.2–1 µg/mL | Cell culture | First independent replication of telomere elongation, 2025 |

**There is no published human subcutaneous or intramuscular amount for synthetic Epitalon.** No pharmacokinetic data exists for either substance. Nearly all of this work comes from one research group in St Petersburg, is largely untranslated, and uses non-standard endpoints such as “functional age”; an independent review notes no result has been replicated outside that group. Epithalamin is registered as a medicine in Russia only; synthetic Epitalon is approved nowhere and has zero registered clinical trials.

### Sources

Schneider-Helmert 1981 — [PMID 6895513](https://pubmed.ncbi.nlm.nih.gov/6895513/) ·
Monti 1987 — [PMID 3583493](https://pubmed.ncbi.nlm.nih.gov/3583493/) ·
Bes 1992 — [PMID 1299794](https://pubmed.ncbi.nlm.nih.gov/1299794/)
DSIP pharmacokinetics — [PMID 6379493](https://pubmed.ncbi.nlm.nih.gov/6379493/)
Korkushko 2006, Epithalamin 12-year follow-up — [PMID 17426848](https://pubmed.ncbi.nlm.nih.gov/17426848/)
Epitalon / Epithalamin review with dose tables, IJMS 2025 — [PMC11943447](https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/)
Independent replication, Biogerontology 2025 — [PMC12411320](https://pmc.ncbi.nlm.nih.gov/articles/PMC12411320/)
Independent review incl. approval status — [ADDF Cognitive Vitality](https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Epithalamin-and-Epithalon-Cognitive-Vitality-For-Researchers.pdf)

Sold for research and identification purposes only. Not for human dosing, injection, or ingestion, and not for veterinary use. This page describes published research; it is not instructions for use. For guidance about your own situation, speak with a qualified healthcare professional.

See also our [Sleep and Circadian Research Compounds](https://portaltowellness.net/circadian-kit/) category overview.

---

Source: https://portaltowellness.net/research/dsip-epithalon-what-the-research-says-about-sleep-and-circadian-peptides/
Research use only. Terms: https://portaltowellness.net/research-use-only/